PTU - Polskie Towarzystwo Urologiczne
list of articles:

Results of treatment of patients with paratesticular rhabdomyosarcoma (RMS) in own material
Article published in Urologia Polska 2005/58/1.


Paweł Wiechno, Małgorzata Sadowska, Tomasz Demkow
Klinika Nowotworów Układu Moczowego Centrum Onkologii - Instytut im. M. Skodowskiej-Curie w Warszawie
Kierownik kliniki: dr hab. Tomasz Demkow


Parastesticular Rhabdomyosarcoma, combined treatment, chemotherapy


Parastesticular Rhabdomyosarcoma (RMS) is a rare neoplasm in adults. We present our experience in treatment of such patients.
aim of the study
Assessment of the frequency of paratesticular RMS in patients with a pathologic intrascrotal mass and efficacy of treatment in such cases.
material and methods
1,280 patients with pathologic intrascrotal masses were seen between 1995-2002, and nine of them (0.7%) were diagnosed with paratesticular RMS. The patients' age ranged from 16 to 32 years. The neoplasm was limited to the site of origin in 4 cases. In 5 cases, metastases were present. The primary tumor was removed in all the patients. In 7 cases, IE/PEC chemotherapy was used, retroperitonal lymphadenectomy was performed in 5 cases, whereas radiotherapy was applied to 1 patient. Follow-up time within the group ranged from 13 to 91 months (median - 56).
There was 1 case of progression among 4 patients with paratesticular RMS confined to the scrotum. The other 3, after adjuvant treatment, were free of the disease for +89 to +91 months. Five patients with disseminated disease were treated with IE/PEC chemotherapy and received from 4 to 9 cycles. All the patients were responding to the treatment and 3 of them achieved complete response lasting from +12 to +39 months. Two patients with partial response progressed and died in the 13th and 21st month after the initial diagnosis.
- Paratesticular RMS is an extremely rare neoplasm in adults.
- Paratesticular RMS is a neoplasm of highly chemosensitive type.
- Combined treatment should be applied in patients with Paratesticular RMS.


  1. Didkowska J, Wojciechowska U, Tarkowski W, Zatoński W: Nowotwory złośliwe w Polsce w 2000 roku, Zakład Epidemiologii i Prewencji Nowotworów Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie 2003; 84-86; 100-102.
  2. Ruka W: Mięsaki tkanek miękkich, w: Krzakowski M Onkologia Kliniczna Borgis 2001, tom II, 340-400.
  3. Russo P, Brady MS, Conlon K, Hajdu SI, Fair WR, Herr HW, Brennan MF: Adult urological sarcoma. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021. J Urol 1992; 147: 1032-6; discussion 1036-1037
  4. Kattan J, Culine S, Terrier-Lacombe MJ, Theodore C, Droz JP.: Paratesticular rhabdomyosarcoma in adult patients: 16-year experience at Institut Gustave-Roussy. Department of Medicine, Institut Gustave-Roussy, Villejuif, France. Ann Oncol 1993; 4; 871-875.
  5. Hermans BP, Foster RS, Bihrle R, et al: Is retroperitoneal lymph node dissection necessary for adult paratesticular rhabdomyosarcoma? J Urol 1998; 160: 2074-2098.
  6. Olive D, Flamant F, Zucker JM, et al: Para-aortic lymphadenectomy is not necessary in the treatment of localised paratesticular rhabdomyosarcoma. Cancer 1984; 54; 1283-1287.
  7. Ferrari A, Bisogno G, Casanova M, et al: Paratesticular rhabdomyosarcoma: report from the Italian and German Cooperative Group. J Clin Oncol 2002; 20; 449-455.
  8. Catton CN, Cummings BJ, Fornasier V, et al: Adult paratesticular sarcomas: a review of 21 cases. Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada. J Urol 1991; 146; 342-345.


Paweł Wiechno
Klinika Nowotworów Układu Moczowego
ul. Roentgena 5
02-781 Warszawa
tel. /fax (0... 22) 546 27 22